Femasys achieves australian and new zealand regulatory approvals for femaseed® for first-line infertility treatment and femvue diagnostic

-- milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- atlanta, july 01, 2025 (globe newswire) -- femasys, inc., (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in australia and new zealand for its next-generation infertility solutions: femaseed® for first-line intratubal insemination treatment and femvue® for diagnostic evaluation. “securing regulatory approvals in australia and new zealand mark another important step in expanding global access to our innovative infertility solutions,” said kathy lee-sepsick, ceo and founder of femasys.
FEMY Ratings Summary
FEMY Quant Ranking